PV Bulletin
European Medicines Agency (EMA)European Union

EMA ETF recommends updating COVID-19 vaccines to target XFG variant for 2026/2027 campaign

The Emergency Task Force of the EMA has recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign due to decreased efficacy of existing vaccines.

Primary source: European Medicines Agency (EMA)

PV Impact Brief

MonitoringConfidence: high

What changed

ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters

Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Action needed

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

Relevant for
Regulatory Intelligence LeadSignal Management Lead
Processes impacted
Signal ManagementLabeling
Owner

Regulatory Intelligence Lead

Review cadence

quarterly

Regulatory action details

Action type
Regulatory Recommendation / Public Health Communication
Publication date
2026-05-29
Last updated
2026-05-29
Safety issue
Decreased efficacy of existing vaccines against the evolving XFG variant of COVID-19.

Affected products

  • COVID-19 vaccines
    Marketing authorisation holders (various)

PV internal implications

Requires monitoring of vaccine efficacy signals and potential preparation for strain change variations.

View regulator source

Evidence and confidence

Confidence: highSource updated: May 29, 2026

Full briefing

Practical implication

Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

The EMA ETF recommends updating COVID-19 vaccines to target the XFG variant for the 2026/2027 campaign, citing decreased efficacy of current vaccines against the evolving variant.

What changed: ETF recommended that marketing authorisation holders update their COVID-19 vaccines to target the XFG variant for the 2026/2027 vaccination campaign.

Why it matters: Decreased efficacy of existing vaccines against the XFG variant could reduce protection against COVID-19, necessitating vaccine strain updates.

Practical implication: Marketing authorisation holders should prepare to update their COVID-19 vaccines to target the XFG variant for the upcoming campaign; monitor for further regulatory guidance and prepare for potential strain change submissions.

View original source

Published from the Firecrawl agent regulatory extraction pipeline.

#Safety Signals#Vaccine Updates#Regulatory Recommendation / Public Health Communication#European Medicines Agency (EMA)#other#firecrawl-agent#regulatory-extraction

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward
publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Updated eCTD v4.0 technical validation criteria

Urgency: High

All electronic PV submissions must undergo new validation checks in accordance with the updated criteria to ensure compliance and accuracy.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Technical Guidance
Read impact briefarrow_forward
publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Urgency: High

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward